Published in Cell on July 01, 1984
Diagnosis of chronic myeloid and acute lymphocytic leukemias by detection of leukemia-specific mRNA sequences amplified in vitro. Proc Natl Acad Sci U S A (1988) 4.40
The translocation (6;9), associated with a specific subtype of acute myeloid leukemia, results in the fusion of two genes, dek and can, and the expression of a chimeric, leukemia-specific dek-can mRNA. Mol Cell Biol (1992) 3.12
In vitro transformation of immature hematopoietic cells by the P210 BCR/ABL oncogene product of the Philadelphia chromosome. Proc Natl Acad Sci U S A (1987) 3.03
The t(8;21) translocation in acute myeloid leukemia results in production of an AML1-MTG8 fusion transcript. EMBO J (1993) 3.00
Can, a putative oncogene associated with myeloid leukemogenesis, may be activated by fusion of its 3' half to different genes: characterization of the set gene. Mol Cell Biol (1992) 2.99
Detection of c-abl tyrosine kinase activity in vitro permits direct comparison of normal and altered abl gene products. Mol Cell Biol (1985) 2.91
Lessons learned from the development of an abl tyrosine kinase inhibitor for chronic myelogenous leukemia. J Clin Invest (2000) 2.90
The BCR-ABL oncogene transforms Rat-1 cells and cooperates with v-myc. Mol Cell Biol (1989) 2.87
Amino acid substitutions sufficient to convert the nontransforming p60c-src protein to a transforming protein. Mol Cell Biol (1986) 2.84
Tyrosyl phosphorylation and DNA binding activity of signal transducers and activators of transcription (STAT) proteins in hematopoietic cell lines transformed by Bcr/Abl. J Exp Med (1996) 2.68
Identification of a developmentally regulated protein-tyrosine kinase by using anti-phosphotyrosine antibodies to screen a cDNA expression library. Proc Natl Acad Sci U S A (1989) 2.60
ret transforming gene encodes a fusion protein homologous to tyrosine kinases. Mol Cell Biol (1987) 2.48
Induction of a chronic myelogenous leukemia-like syndrome in mice with v-abl and BCR/ABL. Proc Natl Acad Sci U S A (1990) 2.36
Activation of the receptor kinase domain of the trk oncogene by recombination with two different cellular sequences. EMBO J (1988) 2.19
A coiled-coil oligomerization domain of Bcr is essential for the transforming function of Bcr-Abl oncoproteins. Mol Cell Biol (1993) 2.18
Two forms of the basic fibroblast growth factor receptor-like mRNA are expressed in the developing mouse brain. Proc Natl Acad Sci U S A (1990) 2.17
Generation of the AML1-EVI-1 fusion gene in the t(3;21)(q26;q22) causes blastic crisis in chronic myelocytic leukemia. EMBO J (1994) 2.12
Activation of tyrosinase kinase and microfilament-binding functions of c-abl by bcr sequences in bcr/abl fusion proteins. Mol Cell Biol (1991) 2.06
bcr-abl, the hallmark of chronic myeloid leukaemia in man, induces multiple haemopoietic neoplasms in mice. EMBO J (1990) 2.00
Overlapping cDNA clones define the complete coding region for the P210c-abl gene product associated with chronic myelogenous leukemia cells containing the Philadelphia chromosome. Proc Natl Acad Sci U S A (1986) 1.97
Bcr-Abl oncoproteins bind directly to activators of the Ras signalling pathway. EMBO J (1994) 1.94
Cell lines and clinical isolates derived from Ph1-positive chronic myelogenous leukemia patients express c-abl proteins with a common structural alteration. Proc Natl Acad Sci U S A (1985) 1.94
Activation of the c-abl oncogene by viral transduction or chromosomal translocation generates altered c-abl proteins with similar in vitro kinase properties. Mol Cell Biol (1985) 1.92
Alterations in the p53 gene and the clonal evolution of the blast crisis of chronic myelocytic leukemia. Proc Natl Acad Sci U S A (1989) 1.86
The first intron in the human c-abl gene is at least 200 kilobases long and is a target for translocations in chronic myelogenous leukemia. Mol Cell Biol (1987) 1.73
The chronic myelocytic cell line K562 contains a breakpoint in bcr and produces a chimeric bcr/c-abl transcript. Mol Cell Biol (1986) 1.72
Alternative forms of the BCR-ABL oncogene have quantitatively different potencies for stimulation of immature lymphoid cells. Mol Cell Biol (1989) 1.67
Characterization of the TPR-MET oncogene p65 and the MET protooncogene p140 protein-tyrosine kinases. Proc Natl Acad Sci U S A (1988) 1.64
Expression of the mammalian c-fes protein in hematopoietic cells and identification of a distinct fes-related protein. Mol Cell Biol (1985) 1.57
p53 in chronic myelogenous leukemia in acute phase. Proc Natl Acad Sci U S A (1991) 1.56
The complete coding sequence of arg defines the Abelson subfamily of cytoplasmic tyrosine kinases. Proc Natl Acad Sci U S A (1990) 1.54
Cell lines and peripheral blood leukocytes derived from individuals with chronic myelogenous leukemia display virtually identical proteins phosphorylated on tyrosine residues. Proc Natl Acad Sci U S A (1987) 1.53
Identification and subcellular localization of proteins that are rapidly phosphorylated in tyrosine in response to colony-stimulating factor 1. Proc Natl Acad Sci U S A (1988) 1.51
Tumorigenic activity of the BCR-ABL oncogenes is mediated by BCL2. Proc Natl Acad Sci U S A (1995) 1.49
Mapping of four distinct BCR-related loci to chromosome region 22q11: order of BCR loci relative to chronic myelogenous leukemia and acute lymphoblastic leukemia breakpoints. Proc Natl Acad Sci U S A (1987) 1.49
Applying the discovery of the Philadelphia chromosome. J Clin Invest (2007) 1.46
Evidence for regulation of the human ABL tyrosine kinase by a cellular inhibitor. Proc Natl Acad Sci U S A (1991) 1.46
Circulating heat shock protein 70 and progression in patients with chronic myeloid leukemia. Leuk Res (2008) 1.45
Subcellular localization of Bcr, Abl, and Bcr-Abl proteins in normal and leukemic cells and correlation of expression with myeloid differentiation. J Clin Invest (1993) 1.43
Heterogeneity of chromosome 22 breakpoint in Philadelphia-positive (Ph+) acute lymphocytic leukemia. Proc Natl Acad Sci U S A (1986) 1.41
The TPR-MET oncogenic rearrangement is present and expressed in human gastric carcinoma and precursor lesions. Proc Natl Acad Sci U S A (1991) 1.40
SH1 domain autophosphorylation of P210 BCR/ABL is required for transformation but not growth factor independence. Mol Cell Biol (1993) 1.38
Transcriptional activation of a ras-like gene (kir) by oncogenic tyrosine kinases. Proc Natl Acad Sci U S A (1994) 1.37
Interferon-inducible gene maps to a chromosomal band associated with a (4;11) translocation in acute leukemia cells. Proc Natl Acad Sci U S A (1987) 1.33
Vasodilator-stimulated phosphoprotein regulates proliferation and growth inhibition by nitric oxide in vascular smooth muscle cells. Arterioscler Thromb Vasc Biol (2004) 1.31
The (6;9) chromosome translocation, associated with a specific subtype of acute nonlymphocytic leukemia, leads to aberrant transcription of a target gene on 9q34. Mol Cell Biol (1990) 1.27
cDNA sequence for human bcr, the gene that translocates to the abl oncogene in chronic myeloid leukaemia. EMBO J (1987) 1.26
Treatment for chronic myelogenous leukemia: the long road to imatinib. J Clin Invest (2007) 1.22
Efficient transplantation of BCR-ABL-induced chronic myelogenous leukemia-like syndrome in mice. Proc Natl Acad Sci U S A (1993) 1.22
Monoclonal antibodies specific for v-abl- and c-abl-encoded molecules. J Virol (1986) 1.21
Clonal lymphoid progenitor cell lines expressing the BCR/ABL oncogene retain full differentiative function. Proc Natl Acad Sci U S A (1990) 1.19
Evidence that the phl gene encodes a 160,000-dalton phosphoprotein with associated kinase activity. Mol Cell Biol (1987) 1.18
Phosphotyrosine antibodies identify the p210c-abl tyrosine kinase and proteins phosphorylated on tyrosine in human chronic myelogenous leukemia cells. Mol Cell Biol (1986) 1.17
Synthetic lethal approaches to breast cancer therapy. Nat Rev Clin Oncol (2010) 1.17
Selecting optimal oligonucleotide composition for maximal antisense effect following streptolysin O-mediated delivery into human leukaemia cells. Nucleic Acids Res (1998) 1.17
Expression of bcr and bcr-abl fusion transcripts in normal and leukemic cells. Mol Cell Biol (1987) 1.16
Comparison of constitutional and tumor-associated 11;22 translocations: nonidentical breakpoints on chromosomes 11 and 22. Proc Natl Acad Sci U S A (1986) 1.16
Blastic transformation of p53-deficient bone marrow cells by p210bcr/abl tyrosine kinase. Proc Natl Acad Sci U S A (1996) 1.15
Selective transformation of primitive lymphoid cells by the BCR/ABL oncogene expressed in long-term lymphoid or myeloid cultures. Mol Cell Biol (1988) 1.15
Identification and biochemical characterization of p70TRK, product of the human TRK oncogene. Proc Natl Acad Sci U S A (1987) 1.14
Comparative mapping of the constitutional and tumor-associated 11;22 translocations. Am J Hum Genet (1989) 1.13
Duplication of the bcr and gamma-glutamyl transpeptidase genes. Nucleic Acids Res (1988) 1.12
Biology-driven cancer drug development: back to the future. BMC Biol (2010) 1.12
STAT signaling in the pathogenesis and treatment of cancer. Mol Med (1999) 1.11
A temperature sensitive p210 BCR-ABL mutant defines the primary consequences of BCR-ABL tyrosine kinase expression in growth factor dependent cells. EMBO J (1994) 1.09
Regulated expression of P210 Bcr-Abl during embryonic stem cell differentiation stimulates multipotential progenitor expansion and myeloid cell fate. Proc Natl Acad Sci U S A (2000) 1.09
Cytotoxic T cell response against the chimeric p210 BCR-ABL protein in patients with chronic myelogenous leukemia. J Clin Invest (1998) 1.08
Mutant forms of growth factor-binding protein-2 reverse BCR-ABL-induced transformation. Proc Natl Acad Sci U S A (1995) 1.08
C-abl and bcr are rearranged in a Ph1-negative CML patient. EMBO J (1985) 1.08
Human cancer and cellular oncogenes. Biochem J (1987) 1.07
Coupling between p210bcr-abl and Shc and Grb2 adaptor proteins in hematopoietic cells permits growth factor receptor-independent link to ras activation pathway. J Exp Med (1994) 1.07
Genetic mapping of a major site of phosphorylation in adenovirus type 2 E1A proteins. J Virol (1986) 1.06
The 5' noncoding region of the human leukemia-associated oncogene BCR/ABL is a potent inhibitor of in vitro translation. Mol Cell Biol (1989) 1.00
Tyrosine phosphorylation of p62dok by p210bcr-abl inhibits RasGAP activity. Proc Natl Acad Sci U S A (2000) 1.00
Role of proto-oncogene activation in carcinogenesis. Environ Health Perspect (1992) 0.99
Temperature-sensitive mutants of Abelson murine leukemia virus deficient in protein tyrosine kinase activity. J Virol (1990) 0.98
Induction of platelet-derived growth factor gene expression during megakaryoblastic and monocytic differentiation of human leukemia cell lines. EMBO J (1987) 0.98
Localization of preferential sites of rearrangement within the BCR gene in Philadelphia chromosome-positive acute lymphoblastic leukemia. Proc Natl Acad Sci U S A (1989) 0.97
Molecular analysis of TCRB and ABL in a t(7;9)-containing cell line (SUP-T3) from a human T-cell leukemia. Proc Natl Acad Sci U S A (1987) 0.96
Random mutagenesis reveals residues of JAK2 critical in evading inhibition by a tyrosine kinase inhibitor. PLoS One (2012) 0.96
Normal cellular and transformation-associated abl proteins share common sites for protein kinase C phosphorylation. Mol Cell Biol (1987) 0.96
"Replacement" of COOH-terminal truncation of v-fms with c-fms sequences markedly reduces transformation potential. Proc Natl Acad Sci U S A (1986) 0.96
Molecular mechanisms of cancer. West J Med (1991) 0.95
T-cell immunity to the joining region of p210BCR-ABL protein. Proc Natl Acad Sci U S A (1992) 0.95
PD166326, a novel tyrosine kinase inhibitor, has greater antileukemic activity than imatinib mesylate in a murine model of chronic myeloid leukemia. Blood (2005) 0.94
Inhibition of Bcr serine kinase by tyrosine phosphorylation. Mol Cell Biol (1996) 0.94
Comparison of the specificities and catalytic activities of hammerhead ribozymes and DNA enzymes with respect to the cleavage of BCR-ABL chimeric L6 (b2a2) mRNA. Nucleic Acids Res (1997) 0.94
TPR-MET oncogenic rearrangement: detection by polymerase chain reaction amplification of the transcript and expression in human tumor cell lines. Proc Natl Acad Sci U S A (1990) 0.94
BCR-ABL and v-SRC tyrosine kinase oncoproteins support normal erythroid development in erythropoietin receptor-deficient progenitor cells. Proc Natl Acad Sci U S A (1999) 0.93
The first BCR gene intron contains breakpoints in Philadelphia chromosome positive leukemia. Nucleic Acids Res (1988) 0.93
Differences in oncogenic potency but not target cell specificity distinguish the two forms of the BCR/ABL oncogene. Mol Cell Biol (1991) 0.92
Clinical targeting of mutated and wild-type protein tyrosine kinases in cancer. Mol Cell Biol (2014) 0.92
The amphiphysin-like protein 1 (ALP1) interacts functionally with the cABL tyrosine kinase and may play a role in cytoskeletal regulation. Proc Natl Acad Sci U S A (1997) 0.92
Hyperexpression of interleukin-7 is not necessary or sufficient for transformation of a pre-B lymphoid cell line. Mol Cell Biol (1991) 0.91
Antibody recognition of the tumor-specific bcr-abl joining region in chronic myeloid leukemia. J Exp Med (1989) 0.90
Berbamine exhibits potent antitumor effects on imatinib-resistant CML cells in vitro and in vivo. Acta Pharmacol Sin (2009) 0.90
Philadelphia Chromosome Symposium: commemoration of the 50th anniversary of the discovery of the Ph chromosome. Cancer Genet (2011) 0.89
Characterization of the BCR promoter in Philadelphia chromosome-positive and -negative cell lines. Mol Cell Biol (1991) 0.89
Unique organization of the human BCR gene promoter. Nucleic Acids Res (1990) 0.89
Antibody-based detection of protein phosphorylation status to track the efficacy of novel therapies using nanogram protein quantities from stem cells and cell lines. Nat Protoc (2014) 0.88
Abelson murine leukaemia virus protein is phosphorylated in vitro to form phosphotyrosine. Nature (1980) 6.76
Identification of an Abelson murine leukemia virus-encoded protein present in transformed fibroblast and lymphoid cells. Proc Natl Acad Sci U S A (1978) 6.38
Structure of the Abelson murine leukemia virus genome and the homologous cellular gene: studies with cloned viral DNA. Cell (1980) 5.68
Tyrosine kinase activity and transformation potency of bcr-abl oncogene products. Science (1990) 5.20
Diagnosis of chronic myeloid and acute lymphocytic leukemias by detection of leukemia-specific mRNA sequences amplified in vitro. Proc Natl Acad Sci U S A (1988) 4.40
BCR first exon sequences specifically activate the BCR/ABL tyrosine kinase oncogene of Philadelphia chromosome-positive human leukemias. Mol Cell Biol (1991) 4.31
Relationship of retrovirus polyprotein cleavages to virion maturation studied with temperature-sensitive murine leukemia virus mutants. J Virol (1978) 4.06
Prostate stem cell antigen: a cell surface marker overexpressed in prostate cancer. Proc Natl Acad Sci U S A (1998) 3.89
Long-term culture of B lymphocytes and their precursors from murine bone marrow. Proc Natl Acad Sci U S A (1982) 3.74
Differential expression of myc family genes during murine development. Nature (1986) 3.57
The chronic myelogenous leukemia-specific P210 protein is the product of the bcr/abl hybrid gene. Science (1986) 3.53
Conjugation in Saccharomyces cerevisiae. Annu Rev Cell Biol (1988) 3.47
Progression of metastatic human prostate cancer to androgen independence in immunodeficient SCID mice. Nat Med (1997) 3.46
Abelson murine leukemia virus-induced tumors elicit antibodies against a host cell protein, P50. J Virol (1980) 3.30
In vitro transformation of immature hematopoietic cells by the P210 BCR/ABL oncogene product of the Philadelphia chromosome. Proc Natl Acad Sci U S A (1987) 3.03
Cellular maturation of oncornavirus glycoproteins: topological arrangement of precursor and product forms in cellular membranes. Virology (1977) 3.01
Detection of c-abl tyrosine kinase activity in vitro permits direct comparison of normal and altered abl gene products. Mol Cell Biol (1985) 2.91
The BCR-ABL oncogene transforms Rat-1 cells and cooperates with v-myc. Mol Cell Biol (1989) 2.87
A normal cell protein cross-reactive to the major Abelson murine leukaemia virus gene product. Nature (1979) 2.85
Lethal effect of the Abelson murine leukemia virus transforming gene product. Cell (1981) 2.82
Brief report: a point mutation in the SH2 domain of Bruton's tyrosine kinase in atypical X-linked agammaglobulinemia. N Engl J Med (1994) 2.75
Activation of BTK by a phosphorylation mechanism initiated by SRC family kinases. Science (1996) 2.71
Dominant negative MYC blocks transformation by ABL oncogenes. Cell (1992) 2.64
Two new S-phase-specific genes from Saccharomyces cerevisiae. Yeast (1997) 2.64
Prostate stem cell antigen (PSCA) expression increases with high gleason score, advanced stage and bone metastasis in prostate cancer. Oncogene (2000) 2.61
Retracted Lysophosphatidylcholine as a ligand for the immunoregulatory receptor G2A. Science (2001) 2.52
Structure of the murine leukemia virus envelope glycoprotein precursor. J Virol (1979) 2.51
Preparation of syngeneic tumor regressor serum reactive with the unique determinants of the Abelson murine leukemia virus-encoded P120 protein at the cell surface. J Virol (1979) 2.50
Leukemia and the disruption of normal hematopoiesis. Cell (1991) 2.43
Evidence for clonal outgrowth of androgen-independent prostate cancer cells from androgen-dependent tumors through a two-step process. Cancer Res (1999) 2.38
Btk/Tec kinases regulate sustained increases in intracellular Ca2+ following B-cell receptor activation. EMBO J (1998) 2.36
Induction of a chronic myelogenous leukemia-like syndrome in mice with v-abl and BCR/ABL. Proc Natl Acad Sci U S A (1990) 2.36
BCR sequences essential for transformation by the BCR-ABL oncogene bind to the ABL SH2 regulatory domain in a non-phosphotyrosine-dependent manner. Cell (1991) 2.29
A single bone marrow-derived stromal cell type supports the in vitro growth of early lymphoid and myeloid cells. Cell (1987) 2.27
S. cerevisiae alpha pheromone receptors activate a novel signal transduction pathway for mating partner discrimination. Cell (1991) 2.25
Structural characteristics of some murine RNA tumor viruses studied by lactoperoxidase iodination. Proc Natl Acad Sci U S A (1973) 2.18
A transformation-defective mutant of Abelson murine leukemia virus lacks protein kinase activity. Proc Natl Acad Sci U S A (1980) 2.16
Abelson murine leukemia virus mutants with alterations in the virus-specific P120 molecule. J Virol (1980) 2.16
The viral and cellular forms of the Abelson (abl) oncogene. Adv Virus Res (1988) 2.10
Regulation of Btk function by a major autophosphorylation site within the SH3 domain. Immunity (1996) 2.07
The BCR gene encodes a novel serine/threonine kinase activity within a single exon. Cell (1991) 2.06
Binding of beta gamma subunits of heterotrimeric G proteins to the PH domain of Bruton tyrosine kinase. Proc Natl Acad Sci U S A (1994) 2.04
The effect of regional gene therapy with bone morphogenetic protein-2-producing bone-marrow cells on the repair of segmental femoral defects in rats. J Bone Joint Surg Am (1999) 2.00
Involvement of Bruton's tyrosine kinase in FcepsilonRI-dependent mast cell degranulation and cytokine production. J Exp Med (1998) 1.99
Murine B cell lymphopoiesis in long term culture. J Immunol Methods (1984) 1.98
Overlapping cDNA clones define the complete coding region for the P210c-abl gene product associated with chronic myelogenous leukemia cells containing the Philadelphia chromosome. Proc Natl Acad Sci U S A (1986) 1.97
The CML-specific P210 bcr/abl protein, unlike v-abl, does not transform NIH/3T3 fibroblasts. Science (1987) 1.94
Cell lines and clinical isolates derived from Ph1-positive chronic myelogenous leukemia patients express c-abl proteins with a common structural alteration. Proc Natl Acad Sci U S A (1985) 1.94
Oligomerization of the ABL tyrosine kinase by the Ets protein TEL in human leukemia. Mol Cell Biol (1996) 1.93
Only site-directed antibodies reactive with the highly conserved src-homologous region of the v-abl protein neutralize kinase activity. J Virol (1984) 1.93
Activation of the c-abl oncogene by viral transduction or chromosomal translocation generates altered c-abl proteins with similar in vitro kinase properties. Mol Cell Biol (1985) 1.92
Vesicular stomatitis virus glycoprotein is necessary for H-2-restricted lysis of infected cells by cytotoxic T lymphocytes. Proc Natl Acad Sci U S A (1978) 1.88
Species-specific oligodeoxynucleotide probes for the identification of periodontal bacteria. J Clin Microbiol (1990) 1.86
Abelson murine leukemia virus mutants deficient in kinase activity and lymphoid cell transformation. J Virol (1980) 1.85
Phosphatidylinositol 3-kinase-gamma activates Bruton's tyrosine kinase in concert with Src family kinases. Proc Natl Acad Sci U S A (1997) 1.85
Temporal differences in the activation of three classes of non-transmembrane protein tyrosine kinases following B-cell antigen receptor surface engagement. Proc Natl Acad Sci U S A (1994) 1.83
Abelson virus-infected cells can exhibit restricted in vitro growth and low oncogenic potential. J Virol (1981) 1.80
Mechanism of formation of pseudotypes between vesicular stomatitis virus and murine leukemia virus. Cell (1977) 1.80
Impaired expansion of mouse B cell progenitors lacking Btk. Immunity (1995) 1.79
Unique forms of the abl tyrosine kinase distinguish Ph1-positive CML from Ph1-positive ALL. Science (1987) 1.76
Genome structure of Abelson murine leukemia virus variants: proviruses in fibroblasts and lymphoid cells. J Virol (1981) 1.73
Alternative signals to RAS for hematopoietic transformation by the BCR-ABL oncogene. Cell (1995) 1.73
The role of Bruton's tyrosine kinase in B-cell development and function: a genetic perspective. Immunol Rev (2000) 1.71
Alternative forms of the BCR-ABL oncogene have quantitatively different potencies for stimulation of immature lymphoid cells. Mol Cell Biol (1989) 1.67
Regulation of Btk by Src family tyrosine kinases. Mol Cell Biol (1996) 1.66
Anti-PSCA mAbs inhibit tumor growth and metastasis formation and prolong the survival of mice bearing human prostate cancer xenografts. Proc Natl Acad Sci U S A (2001) 1.65
Initiation of deregulated growth of multipotent progenitor cells by bcr-abl in vitro. Science (1992) 1.62
Polypeptides of Moloney sarcoma-leukemia virions: their resolution and incorporation into extracellular virions. Virology (1974) 1.61
Xid-like phenotypes: a B cell signalosome takes shape. Immunity (2000) 1.60
Expression of a distinctive BCR-ABL oncogene in Ph1-positive acute lymphocytic leukemia (ALL). Science (1988) 1.59
Genetic requirement for Ras in the transformation of fibroblasts and hematopoietic cells by the Bcr-Abl oncogene. J Exp Med (1995) 1.59
Transformation of immature lymphoid cells by Abelson murine leukemia virus. Immunol Rev (1979) 1.58
Mice lacking the orphan G protein-coupled receptor G2A develop a late-onset autoimmune syndrome. Immunity (2001) 1.58
A GDP dissociation inhibitor that serves as a GTPase inhibitor for the Ras-like protein CDC42Hs. Science (1992) 1.58
Activation of Bruton's tyrosine kinase (BTK) by a point mutation in its pleckstrin homology (PH) domain. Immunity (1995) 1.56
Tyrosine phosphorylation and activation of Bruton tyrosine kinase upon Fc epsilon RI cross-linking. Mol Cell Biol (1994) 1.54
Redundant and opposing functions of two tyrosine kinases, Btk and Lyn, in mast cell activation. J Immunol (2000) 1.54
Differential complementation of Bcr-Abl point mutants with c-Myc. Science (1994) 1.52
Progression of the transformed phenotype in clonal lines of Abelson virus-infected lymphocytes. Mol Cell Biol (1983) 1.48
Evidence for regulation of the human ABL tyrosine kinase by a cellular inhibitor. Proc Natl Acad Sci U S A (1991) 1.46
Btk dosage determines sensitivity to B cell antigen receptor cross-linking. Proc Natl Acad Sci U S A (1997) 1.42
Association and activation of Btk and Tec tyrosine kinases by gp130, a signal transducer of the interleukin-6 family of cytokines. Blood (1995) 1.42
Synergism of v-myc and v-Ha-ras in the in vitro neoplastic progression of murine lymphoid cells. Mol Cell Biol (1986) 1.42
Regional gene therapy with a BMP-2-producing murine stromal cell line induces heterotopic and orthotopic bone formation in rodents. J Orthop Res (1998) 1.41
Significance of residual leukaemia transcripts after bone marrow transplant for CML. Lancet (1990) 1.40
Sole BCR-ABL inhibition is insufficient to eliminate all myeloproliferative disorder cell populations. Proc Natl Acad Sci U S A (2004) 1.39
In vivo tyrosine phosphorylations of the Abelson virus transforming protein are absent in its normal cellular homolog. Cell (1982) 1.39
SH1 domain autophosphorylation of P210 BCR/ABL is required for transformation but not growth factor independence. Mol Cell Biol (1993) 1.38
Btk function in B cell development and response. Semin Immunol (1998) 1.38
Role of Bruton's tyrosine kinase in immunodeficiency. Curr Opin Immunol (1994) 1.37
Long-term culture of murine bone marrow precursors of B lymphocytes. Methods Enzymol (1987) 1.37
Bcl-2-independent Bcr-Abl-mediated resistance to apoptosis: protection is correlated with up regulation of Bcl-xL. Oncogene (1998) 1.37
Differentiation of cloned populations of immature B cells after transformation with Abelson murine leukemia virus. Cell (1983) 1.36
A limited set of SH2 domains binds BCR through a high-affinity phosphotyrosine-independent interaction. Mol Cell Biol (1992) 1.35